Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Elite Clinical Studies LLC

Neither a doctor nor a teaching hospital

Research payments

$2,155,174

232 payments

Through program year 2025, Elite Clinical Studies LLC is reported as receiving $2,155,174 in research payments, across 232 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $853,126 43
2024 Research $428,080 51
2023 Research $438,798 52
2022 Research $65,422 28
2021 Research $82,585 21
2020 Research $144,079 30
2019 Research $143,083 7

Breakdown

Who paid Research payments · program years 2019–2025
  1. Eli Lilly and Company $1,068,095 22 payments
  2. Amgen Inc. $424,756 22 payments
  3. Acrotech Biopharma LLC $91,480 16 payments
  4. Takeda Pharmaceuticals U.S.A., Inc. $90,963 54 payments
  5. Verona Pharma, Inc. $89,809 6 payments
  6. Pfizer Inc. $74,028 13 payments
  7. Indivior Inc. $73,149 10 payments
  8. Biohaven Pharmaceutical Holding Company Ltd. $53,203 9 payments
  9. GRT US Holding, Inc. $42,347 18 payments
  10. Braintree Laboratories, Inc. $40,312 12 payments
Studies the money was for Research payments · program years 2019–2025
  1. A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity Or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (Attain-Hypertension). Isas-Gzl1;Gzl2 $245,872 2 payments
  2. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(A) Who Have Established Atherosclerotic Cardiovascular Disease Or Are at Risk for A First Cardiovascular Event - Acclaim-Lp(A) $234,936 4 payments
  3. FOURIER OLE (Ph 4) $221,180 10 payments
  4. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $165,414 4 payments
  5. A Phase 3 Randomized Double-Blind Placebo-Controlled Study to Investigate the Effect of Tirzepatide on the Reduction of Morbidity and Mortality in Adults With Obesity $155,955 2 payments
  6. A Phase 4 Openlabel Study to Evaluate the Safety and Tolerability of Daily Dosing of Rimegepant in Episodic Migraine Prevention $98,195 15 payments
  7. A Phase IIb Ensifentrine-glycopyrrolate Fixed-dose Combination Dose Ranging Study in Subjects With COPD $89,809 6 payments
  8. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $85,487 3 payments
  9. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and the Decline in Kidney Function in Participants With Body Mass Index Greater Than 27 KG M2 and Atherosclerotic Cardiovascular Disease and Or Chronic Kidney Disease $74,336 1 payment
  10. A Phase II Double Blind, Placebo Controlled, Randomised, Dose-Ranging Study to Assess the Safety and Efficacy of Indv-2000 Over 3 Months in Treatment Seeking Individuals With Opioid Use Disorder $73,149 10 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record